Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + PD-1 + Chemo in Advanced G/GEJ Cancer
NCT06158919Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Fudan University. Started Nov 2023; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06158919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158919.